| |

Uncertainly, Worry, and Hope Characterize the Experience of Mesothelioma

experience of mesothelioma

The experience of mesothelioma is characterized by uncertainty and worry for some patients. But the same patients say they are also optimistic and hopeful. 

These findings come from in-depth interviews with seven people with pleural mesothelioma. They were all patients at Penn-Presbyterian Medical Center in Philadelphia. 

This is not the first study on the lived experience of mesothelioma. But the authors say American mesothelioma patients are underrepresented in the medical literature. The US has a higher number of mesothelioma deaths each year than any other country. 

The new study shows the experience of these patients is much like that of mesothelioma patients elsewhere in the world. 

Fostering Understanding, Identifying Needs

Mesothelioma is an extremely rare cancer with a poor prognosis. It grows faster than most other cancers. And there are fewer treatment options. These and other factors mean the experience of mesothelioma is different than that of other cancers. 

The authors of the new study call it a “descriptive phenomenological research study”. They used patient interviews to get a sense of what it is like to live with mesothelioma

One major goal was to help healthcare providers understand their mesothelioma patients better. Another was to highlight needs that are not being met. 

Three Major Themes in The Experience of Mesothelioma

The patient interviews revealed three major themes around the experience of mesothelioma. 

The first was worry and uncertainty about the future. Pleural mesothelioma often fails to respond to standard cancer treatments. It is hard to predict in advance which patients will respond and which will not. This makes it difficult for doctors to offer an accurate prognosis. 

The second theme that emerged was value in relationships. As patients’ mesothelioma progressed, they said their close relationships were more important than ever. Some patients said they felt isolated. 

The third theme had to do with adapting to a “new norm”. The experience of mesothelioma typically includes symptoms like shortness of breath and fatigue. Patients talked about having to change their lifestyles to account for these limitations. 

“However, participants also expressed feelings of hope and optimism,” writes Suzanne Walker, whose name appears first on the paper. Researchers around the globe are working to develop new mesothelioma treatments. Some of the most promising emerging therapies center on genes and the immune system.

Communication is Key

One big thing mesothelioma patients in the study said they wanted was clear information from their doctor. Communication with the healthcare team had a direct impact on their experience of mesothelioma. 

The authors conclude, “Timely, coordinated, and personalized care as well as skilled communication should be the cornerstone of care for persons with malignant pleural mesothelioma.”

They say healthcare providers need to help patients cope with the uncertainty of a mesothelioma diagnosis. They should also be aware of the “high symptom burden” of this disease and find ways to help patients feel less isolated. 

Previous studies show patients benefit from discussing their experience of mesothelioma with others. The benefits are seen in both live and virtual support groups.

Source:

Walker, SL, et al, “The Lived Experience of Persons With Malignant Pleural Mesothelioma in the United States”, December 27, 2019, Cancer Nursing, Epub ahead of print, https://insights.ovid.com/crossref?an=00002820-900000000-98995

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…